Literature DB >> 11959761

Characterisation of the cell type-specificity of collagenase 3 mRNA expression in comparison with membrane type 1 matrix metalloproteinase and gelatinase A in the synovial membrane in rheumatoid arthritis.

P K Petrow1, D Wernicke, C Schulze Westhoff, K M Hummel, R Bräuer, J Kriegsmann, E Gromnica-Ihle, R E Gay, S Gay.   

Abstract

OBJECTIVE: To study the pattern and cell type-specificity of collagenase 3, membrane-type 1 matrix metalloproteinase (MT1-MMP), and gelatinase A mRNA expression in the synovial membrane in rheumatoid arthritis (RA).
METHODS: The mRNA expression of collagenase 3, MT1-MMP, and gelatinase A was characterised by northern blot analysis, reverse transcriptase-polymerase chain reaction, and in situ hybridisation. In situ hybridisation was performed in combination with the immunohistochemical detection of cell type-specific antigens.
RESULTS: Synovial membrane specimens from 19 of 21 patients with RA expressing collagenase 3 mRNA were positive for MT1-MMP and gelatinase A mRNA. In control samples from patients without destructive inflammatory joint diseases collagenase 3 mRNA was not expressed and only in two of seven cases was a coexpression of MT1-MMP and gelatinase A mRNA detected. Fibroblast-like cells of the synovial membrane were found to be the predominant source of collagenase 3, MT1-MMP, and gelatinase A mRNA expression in lining and sublining layers as well as at the synovial membrane-cartilage interface. Additionally, the expression of MT1-MMP mRNA was detected in endothelial cells. Collagenase 3 mRNA expression was found in about 5% of CD68 positive macrophages.
CONCLUSIONS: Collagenase 3 mRNA is expressed simultaneously with MT1-MMP and gelatinase A mRNA in fibroblast-like cells of the synovial membrane in RA. These results suggest (a) a broad extracellular proteolytic potential of fibroblast-like cells and (b) an important role of cell surface associated procollagenase 3 activation by MT1-MMP and gelatinase A for cartilage degradation by invading fibroblast-like cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11959761      PMCID: PMC1754087          DOI: 10.1136/ard.61.5.391

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  35 in total

1.  Collagenase-3 (matrix metalloprotease 13) is preferentially localized in the deep layer of human arthritic cartilage in situ: in vitro mimicking effect by transforming growth factor beta.

Authors:  F Moldovan; J P Pelletier; J Hambor; J M Cloutier; J Martel-Pelletier
Journal:  Arthritis Rheum       Date:  1997-09

2.  Cloning, sequencing and characterization of the 5'-flanking region of the human collagenase-3 gene.

Authors:  G Tardif; J P Pelletier; M Dupuis; J E Hambor; J Martel-Pelletier
Journal:  Biochem J       Date:  1997-04-01       Impact factor: 3.857

3.  The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction.

Authors:  V Knäuper; S Cowell; B Smith; C López-Otin; M O'Shea; H Morris; L Zardi; G Murphy
Journal:  J Biol Chem       Date:  1997-03-21       Impact factor: 5.157

4.  Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme.

Authors:  V Knäuper; H Will; C López-Otin; B Smith; S J Atkinson; H Stanton; R M Hembry; G Murphy
Journal:  J Biol Chem       Date:  1996-07-19       Impact factor: 5.157

5.  The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3.

Authors:  H Will; S J Atkinson; G S Butler; B Smith; G Murphy
Journal:  J Biol Chem       Date:  1996-07-19       Impact factor: 5.157

6.  Structural analysis and promoter characterization of the human collagenase-3 gene (MMP13).

Authors:  A M Pendás; M Balbín; E Llano; M G Jiménez; C López-Otín
Journal:  Genomics       Date:  1997-03-01       Impact factor: 5.736

7.  A new double labeling technique for combined in situ hybridization and immunohistochemical analysis.

Authors:  J Kriegsmann; G Keyszer; T Geiler; R E Gay; S Gay
Journal:  Lab Invest       Date:  1994-12       Impact factor: 5.662

8.  Biochemical characterization of human collagenase-3.

Authors:  V Knäuper; C López-Otin; B Smith; G Knight; G Murphy
Journal:  J Biol Chem       Date:  1996-01-19       Impact factor: 5.157

9.  Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage.

Authors:  P G Mitchell; H A Magna; L M Reeves; L L Lopresti-Morrow; S A Yocum; P J Rosner; K F Geoghegan; J E Hambor
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

10.  Cloning of collagenase 3 from the synovial membrane and its expression in rheumatoid arthritis and osteoarthritis.

Authors:  D Wernicke; C Seyfert; B Hinzmann; E Gromnica-Ihle
Journal:  J Rheumatol       Date:  1996-04       Impact factor: 4.666

View more
  9 in total

1.  Alpinia galanga extracts downregulate interleukin-1β-induced matrix metalloproteinases expression in human synovial fibroblasts.

Authors:  Peraphan Pothacharoen; Kanyamas Choocheep; Thanyaluck Phitak; Wilart Pompimon; Prachya Kongtawelert
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-12-04       Impact factor: 2.416

2.  RelA is required for IL-1beta stimulation of Matrix Metalloproteinase-1 expression in chondrocytes.

Authors:  L Raymond; S Eck; E Hays; I Tomek; S Kantor; M Vincenti
Journal:  Osteoarthritis Cartilage       Date:  2006-11-13       Impact factor: 6.576

3.  Expression and localisation of the new metalloproteinase inhibitor RECK (reversion inducing cysteine-rich protein with Kazal motifs) in inflamed synovial membranes of patients with rheumatoid arthritis.

Authors:  P L E M van Lent; P N Span; A W Sloetjes; T R D J Radstake; A W T van Lieshout; J J T M Heuvel; C G J Sweep; W B van den Berg
Journal:  Ann Rheum Dis       Date:  2004-10-14       Impact factor: 19.103

4.  Osteopontin is associated with increased arterial stiffness in rheumatoid arthritis.

Authors:  Laura Bazzichi; Lorenzo Ghiadoni; Alessandra Rossi; Melania Bernardini; Mario Lanza; Francesca De Feo; Camillo Giacomelli; Ilaria Mencaroni; Katia Raimo; Marco Rossi; Anna Maria Mazzone; Stefano Taddei; Stefano Bombardieri
Journal:  Mol Med       Date:  2009-06-18       Impact factor: 6.354

5.  Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritis.

Authors:  Angela Pakozdi; Mohammad A Amin; Christian S Haas; Rita J Martinez; G Kenneth Haines; Lanie L Santos; Eric F Morand; John R David; Alisa E Koch
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

6.  Discoidin domain receptor 2 mediates collagen-induced activation of membrane-type 1 matrix metalloproteinase in human fibroblasts.

Authors:  Iwona Majkowska; Yasuyuki Shitomi; Noriko Ito; Nathanael S Gray; Yoshifumi Itoh
Journal:  J Biol Chem       Date:  2017-03-07       Impact factor: 5.157

7.  Icariin Regulates Cellular Functions and Gene Expression of Osteoarthritis Patient-Derived Human Fibroblast-Like Synoviocytes.

Authors:  Lianhong Pan; Yonghui Zhang; Na Chen; Li Yang
Journal:  Int J Mol Sci       Date:  2017-12-08       Impact factor: 5.923

8.  Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis.

Authors:  Astrid Jüngel; Caroline Ospelt; Mark Lesch; Melissa Thiel; Teresa Sunyer; Olivier Schorr; Beat A Michel; Renate E Gay; Christoph Kolling; Craig Flory; Steffen Gay; Michel Neidhart
Journal:  Ann Rheum Dis       Date:  2009-06-03       Impact factor: 19.103

Review 9.  Endothelial cell phenotypes in the rheumatoid synovium: activated, angiogenic, apoptotic and leaky.

Authors:  Jim Middleton; Laure Americh; Regis Gayon; Denis Julien; Luc Aguilar; Francois Amalric; Jean-Philippe Girard
Journal:  Arthritis Res Ther       Date:  2004-03-08       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.